DARPA's RAPIID Program Aims for Shelf-Stable Blood Substitute by FY2029
DARPA's RAPIID program intends to create synthetic blood substitutes for battlefield use, targeting FDA approval by FY2029. The program seeks proposals addressing blood component development and delivery technologies, presenting a robust opportunity landscape for companies in medical innovation and regulatory compliance.